Concord Health Partners Research
Investment Thesis
Concord Health Partners is a healthcare-focused growth equity firm founded in 2017 by James T. Olsen (former Managing Director and Group Head of Healthcare Investment Banking at Jefferies) and Joseph R. Swedish (former CEO of Anthem/Elevance Health). The firm's core thesis is that healthcare is a highly complex, heavily regulated industry where clinical, policy, reimbursement, and technology considerations are deeply intertwined, and that deep domain expertise plus a proprietary network of strategic relationships is required to identify and de-risk compelling opportunities. Concord positions itself less as passive capital and more as a "strategic capital partner," pairing investment with board leadership, commercial introductions, and operating expertise sourced from a broad bench of healthcare executives (many of whom sit on the firm as Executive Partners or LP-advisors).
Sector Focus
Concord invests exclusively in healthcare, with a strong tilt toward technology-enabled services and software that improve cost, quality, or access. Observed sub-themes across the portfolio include value-based / risk-bearing care enablement (Thyme Care in oncology), revenue cycle management and AI-driven back-office automation (Smarter Technologies, which combines SmarterDx and Access Healthcare), care navigation and patient activation (Loyal Health, acquired by portfolio company Clarify Health in 2026), network intelligence and outcomes analytics (Clarify Health), virtual/telehealth psychiatry (Iris Telehealth), digital mental health (NeuroFlow, Learn to Live), critical care telehealth (Hicuity Health, formerly Advanced ICU Care), post-acute care analytics (Post Acute Analytics), AI clinical decision support (Mednition), medical devices (Highridge Medical, Accelus), and diagnostic imaging networks (Scan.com).
Stage Focus
Concord describes its target as "innovative growth-stage" and "expansion-stage" healthcare companies. Historical deals span an early-stage-focused $50M fund (launched with the American Hospital Association in 2019) through growth-equity checks in later-stage, revenue-generating companies (e.g., its investment alongside strategic and institutional investors in Thyme Care's $125M+ Series E at a >$2B valuation in 2026). The firm both leads rounds for less mature portfolio companies (e.g., leading Mednition's $10M Series A in 2019) and participates as one of several institutional/strategic co-investors in larger, later-stage rounds.
Check Size
No explicit check-size range is published on the firm's site or in secondary sources reviewed; individual disclosed deal sizes range from roughly $10M (Mednition Series A, led) up to participation in $125M+ rounds (Thyme Care Series E) alongside strategic investors, suggesting flexibility across a wide range depending on lead vs. follow role.
Lead Tendency
Mixed. Concord has led early-stage rounds (Mednition) but also regularly participates alongside strategics and other institutional investors in larger growth rounds (Thyme Care, alongside Morgan Health, Humana, CVS Health Ventures, AlleyCorp, HealthQuest Capital, Foresite Capital, Frist Cressey Ventures, Town Hall Ventures, and a16z Bio + Health).
Recent Activity
Concord has raised at least three funds: a $50M early-stage vehicle launched with the American Hospital Association (2019), Concord Innovation Fund II at $150M (final close September 2022), and Concord Innovation Fund III, which was targeting $250M as of a 2024 regulatory filing. Reported combined AUM across vehicles is approximately $316M per third-party trackers. Portfolio company Highridge Medical was Concord's most recent disclosed new investment (September 2025). In 2026, portfolio activity has been notably active: Clarify Health named co-founder Todd Gottula CEO in May 2026, Thyme Care was named to the CNBC Disruptor 50 list in May 2026, Clarify Health acquired Loyal Health in June 2026, Concord participated in Thyme Care's $125M+ Series E in September 2026, and portfolio company Scan.com raised $220M in August 2026 to build out a national medical imaging network.
Portfolio Highlights
Notable current and recent portfolio companies include Thyme Care (oncology care, >$2B valuation), Clarify Health (healthcare outcomes/network intelligence, now including Loyal Health), Smarter Technologies (RCM automation, combining SmarterDx and Access Healthcare), Scan.com (medical imaging network, $220M raise), Highridge Medical and Accelus (medical devices/spine technology), Iris Telehealth, NeuroFlow, Cedar, Hicuity Health, Post Acute Analytics, Mednition, and Learn to Live.
Team
- James T. Olsen — Founder & Managing Partner. Former Managing Director and Group Head, Healthcare Investment Banking at Jefferies; 20+ years healthcare investment banking experience.
- Benson Jose — Partner / COO / CFO.
- Joseph R. Swedish — Partner Emeritus (Co-Founder). Former Chairman, President & CEO of Anthem (now Elevance Health).
- George Hoffmann — Principal.
- Edward Abraham — Principal.
- Robert B. Schulz — Managing Director (joined 2022, healthcare private equity veteran).
- Brian Gragnolati — Executive Partner (joined 2022, healthcare system executive).
Decision Process
Not explicitly disclosed; the firm is a small, partner-led shop (Olsen, Jose, Swedish, and a small group of Principals/MDs), consistent with a partnership-style decision process rather than a large formal investment committee.
Founder Preferences
Concord favors management teams building technology-enabled or tech-adjacent healthcare businesses that address cost, quality, or access problems in complex, regulated corners of the healthcare system, and that can benefit from Concord's operating network of health-system and payer relationships.
Geographic Focus
Concord is headquartered in Summit, New Jersey, and invests primarily in U.S. healthcare companies; the portfolio is nationally distributed rather than regionally concentrated.